Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Using index level provides a macro view of market direction, helping you balance stock-specific decisions with overall sentiment.
27,685 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
A sweeping move by Spanish regulators targets prediction markets and the platforms that host them. This article expla...
A major Vanguard growth ETF is underperforming the S&P 500 this year. Here's how concentration in mega-cap tech shape...
As Advansix positions itself in a volatile chemical market, understanding advansix (asix) 2025 earnings becomes essen...
Carvana’s stock run looked extraordinary, up 4,300% in three years. But the strongest buy signal wasn’t the hype—it w...
AI champions are racing to fund data centers, but the debt that fuels this surge is drawing scrutiny. This guide expl...
The GLP-1 wave has traders buzzing. While Lilly and Novo Nordisk hold steady as reliable bets, smart portfolios tap i...
A sharp one-week drop surprised many investors. This analysis explains the drivers behind the decline, from KPI discl...
WeWork and Upwork CEOs acknowledge a continuing Gen Z hiring crunch amid AI disruption, stressing mentorship and lead...
Fresh data from Stanford and ADP shows AI exposure weighing on entry-level hiring, challenging hopes that automation ...
When a company's chief financial officer sells a sizable stake, investors want to know what it means. This deep dive ...
NVIDIA posted a blowout quarter as AI demand drives data-center growth, fueling bets that the company will form trill...